A maintenance regimen comprising olaparib and bevacizumab led to greater progression-free survival (PFS) in patients newly diagnosed with advanced ovarian cancer, results of the phase III PAOLA-1/ENGOT-ov25* study showed.
Babies born to mothers exposed to high levels of bisphenol A during pregnancy are at a greater risk of wheezing and poor lung function, according to a new study presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).
Veliparib added onto frontline chemotherapy followed by veliparib maintenance monotherapy (veliparib throughout) significantly prolonged progression-free survival (PFS) in women with newly diagnosed high-grade serous ovarian carcinoma, the phase III placebo-controlled VELIA/GOG-3005 trial has shown.
Women who conceive singleton pregnancies following assisted reproductive technology (ART) may have a higher risk of developing gestational diabetes than those who conceive spontaneously, according to results of a systematic review and meta-analysis presented at EASD 2019.
Women with early breast cancer (BCa) who participated in an exercise and nutrition-based supportive care intervention programme called APAD* while being on a chemoradiotherapy (CRT) regimen had durable improvements in patient-reported outcomes, particularly fatigue and quality of life (QoL), compared with those receiving usual care, the APAD1 study shows.
Sleeping on the back or on the right side during pregnancy was not associated with a higher risk of adverse pregnancy outcomes compared with sleeping on the left, reveals the NuMoM2b* study, contrary to the common belief that pregnant women should sleep on their left side.
Maternal intake of paracetamol during mid-pregnancy was associated with hyperactivity and attention problems in their offspring up to preschool age, although the association was diminished as the children grew older, according to the ALSPAC* study.
Treatment with the selective PARP* 1/2 inhibitor niraparib after a response to first-line platinum-based chemotherapy significantly extends progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, including those at high risk of relapse, according to the PRIMA** study presented at ESMO 2019.